Dr Reddy's inks South East Asia commercialisation, licence pacts with China's Bio-Thera for Stelara, Simponi biosimilars
HYDERABAD: Dr Reddy’s Labs on Wednesday said its subsidiary, Dr Reddy’s Labs SA, has entered into commercialisation and ...
Dr Reddy’s inks exclusive commercialisation pact on biosimilars for Southeast Asia
Bio-Thera and Dr. Reddy's partner for biosimilar commercialization in Southeast Asia, expanding access to affordable ...
Bio-Thera, Dr. Reddy's partner for biosimilar expansion in Southeast Asia
With this partnership, they aim to enhance access to affordable treatments for patients suffering from autoimmune diseases ...
Chinese firm Bio-Thera Solutions, Dr. Reddy’s in pact for proposed biosimilars of J&J
Bio-Thera Solutions and Dr. Reddy’s partner for biosimilar commercialization in Southeast Asia, expanding access to critical treatments.
Drug Store News5d
FDA accepts BLA submission from Dr. Reddy's, Alvotech for proposed Prolia, Xgeva biosimilars
After approval by the FDA, AVT03 is expected to be supplied in a single-dose prefilled syringe containing 60 mg in a 1 ml ...
Finalist: Prem Reddy, M.D., FACC, FCCP
Prem Reddy, M.D., FACC, FCCP, is a physician, entrepreneur and philanthropist. Dr. Reddy was born into a family of proud ...
Morningstar8d
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
Chief Executive Officer, Dr. Reddy’s North America. “This milestone marks an important step in our mission to improve patient lives by expanding access to affordable and quality biologic ...
Yahoo Finance29d
Techademy names Subramanyam Reddy (Subbu), Former UpGrad KnowledgeHut Founder, as CEO
today announced the appointment of Subramanyam Reddy (Subbu) as Co-Founder & Chief Executive Officer. This strategic appointment brings together Techademy's expertise spanning three decades in ...
Dr. Reddy's Laboratories advances Monday, outperforms competitors
Dr. Reddy's Laboratories Ltd. closed 18.99% below its 52-week high of 1,420.20 rupees, which the company reached on August ...
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...